Skip to main content
FDA expands oral JAK abrocitinib to adolescents with AD
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
FDA expands oral JAK abrocitinib to adolescents with AD
User login
Username
Password
Reset your password
Concept
Lead
score
Dermatitis
1
1
Adolescent Medicine
0
1
Biologic Therapy
0
0.54
Child
0
0.28
Atopic Dermatitis
0
1
Pruritus
0
0.19
Toxicology
0
0.19
Tuberculosis
0
0.15
Pediatric Dermatology
0
0.13
Topical Corticosteroid
0
0.13
California
0
0.09
Clinical Research
0
0.09
Corticosteroids
0
0.09
Cytokines
0
0.09
Dermatoses
0
0.09
Eczema
0
0.09
Headache
0
0.09
Healthcare and Medical Technology
0
0.09
Hospital
0
0.09
Immunomodulator
0
0.09
Interleukin
0
0.09
Nasopharyngitis
0
0.09
Nausea
0
0.09
Refractory
0
0.09
Severity Index
0
0.09
Thromboembolism
0
0.09
Thrombosis
0
0.09
Thymus
0
0.09
Topical Medication
0
0.09
Travel Medicine
0
0.09
Specialty
Lead
score
Dermatology
1
1
Family Medicine/Primary Care
0
1
Pediatrics
0
1
Pharmacist
0
0.51
Allergy & Clinical Immunology
0
0.9
Emergency Medicine
0
0.4
Public Health & Prevention
0
0.29
Hospital Medicine
0
0.09
Edit Tags